Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan

Table 2 Study parameter and ranges in one-way sensitivity analysis

Pramater	Values	Range	Ref
CINV related health state probabilities
Complete response in acute phase in PALO regimen	0.918	95% CI	[7]
Complete response in delayed phase in PALO regimen	0.672	95% CI	[7]
Complete response in acute phase in GRA regimen	0.918	95% CI	[7]
Complete response in delayed phase in GRA regimen	0.591	95% CI	[7]
Costs	JPY (USD)	JPY (USD)
Palonosetron 0.75 mg (IV)	14,972 (133.5)	7,486-14,972 (66.7-133.5)	[15]
Granisetoron 1 mg (IV)	1,273 (11.3)	590 -1,273 (5.26-11.3)	[15]
Aprepitantcapusule set (125 mg /80 mg /80 mg) (PO)	11,638.2 (103.8)		[15]
Dexametazone 2 mg (IV)	99 (0.883)		[15]
Dexametazone 4 mg (PO)	34 (0.303)		[15]
Blood test^b	1,580 (14.1)		[16]
Internal medicine for rescue medication for PALO regimen	432 (3.85)	± 30%	[15, 18, 19]
Internal medicine for rescue medication for GRA regimen	5,956.5 (53.1)	± 30%	[15, 18, 19]
Infusion therapy for rescue medication	1,374 (12.3)	± 30%	[15, 16, 18, 19]
Total cost per acute CINV in PALO regimen	432 (3.85)
Total cost per delayed CINV in PALO regimen	2,396 (21.36)
Total cost per acute CINV in GRA regimen	5,956.5 (53.10)
Total cost per delayed CINV in GRA regimen	10,221 (91.12)
Utility values
Complete protection	0.9	± 30%	[13, 14, 20,21,22]
Complete response at best	0.7	± 30%	[13, 14, 20,21,22]
Incomplete response	0.2	± 30%	[13, 14, 20,21,22]

CINV Chemotherapy induced nausea and vomitingn, PALO Palonosetron, GRA Granisetron, CI Confidence interval, JPY Japanese yen, IV Intravenous, PO Oral. Exchange rate, 1 USD = 112.17 JPY

ISSN: 1472-6963